Ranibizumab
( DrugBank: Ranibizumab / KEGG DRUG: Ranibizumab )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 34 | Neurofibromatosis | 1 |
| 166 | Pseudoxanthoma elasticum | 4 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 227 | Osler disease | 1 |
| 301 | Macular dystrophy | 1 |
34. Neurofibromatosis
Clinical trials : 165 / Drugs : 189 - (DrugBank : 83) / Drug target genes : 93 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
166. Pseudoxanthoma elasticum
Clinical trials : 19 / Drugs : 21 - (DrugBank : 7) / Drug target genes : 5 - Drug target pathways : 26
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
227. Osler disease
Clinical trials : 57 / Drugs : 60 - (DrugBank : 20) / Drug target genes : 25 - Drug target pathways : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
301. Macular dystrophy
Clinical trials : 59 / Drugs : 42 - (DrugBank : 14) / Drug target genes : 9 - Drug target pathways : 72
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|